Omnibus Contract Opportunity for Medical Countermeasures

Offerors, consider submitting a proposal through the 2021 Omnibus Broad Agency Announcement (BAA) Development of Medical Countermeasures for Biothreat Agents, Antimicrobial-Resistant Infections, and Emerging Infectious Diseases.

Read the BAA for full details and check whether you have the expertise necessary to carry out the Division of Microbiology and Infectious Diseases (DMID) program objectives.

The BAA supports three distinct scientific areas, summarized below. If you would like to address more than one research area, you must send a separate and distinct proposal for each area.

Research Area 001: Advanced Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases

• Objective: To advance vaccine technologies and platforms that have sufficient proof-of-concept data and/or clinical data to support vaccine development through manufacturing, toxicology testing, and testing in Phase 1 or 2 clinical trials.   
• Anticipated Number of Awards and Total Costs: Across research areas 001 and 002, NIAID anticipates awarding three or more cost-reimbursement completion type contracts for a total cost (direct and indirect costs combined) of up to $11 million for the non-severable base work across all contracts.

Research Area 002: Development of Therapeutic Products for Biodefense, Antimicrobial Resistant (AMR) Infections, and Emerging Infectious Diseases

• Objective: To develop promising new therapeutics to address infections caused by NIAID Category A, B, and C priority pathogens and select bacterial and fungal infections identified in CDC’s Antibiotic Resistance Threats in the United States, 2019 report.
• Number of Awards and Total Costs: Across research areas 001 and 002, NIAID anticipates awarding three or more cost-reimbursement completion type contracts for a total cost (direct and indirect costs combined) of up to $11 million for the non-severable base work across all contracts.

Research Area 003: Advanced Development of Sequencing-Based Diagnostics for Biothreats and Emerging Infectious Diseases

• Objective: To advance the research and development of nucleic acid and protein sequencing solutions on established commercial platforms for the targeted and agnostic detection of biothreat and naturally emerging infectious pathogens.
• Number of Awards and Total Costs: NIAID anticipates awarding one or more cost-reimbursement completion type contracts for a total cost (direct and indirect costs combined) of up to $4 million for the non-severable base work across all contracts.

For All Three Research Areas

• Performance Period: Not to exceed five years for the base plus any options you propose.
• Contact: Direct inquiries to Alexandra Buck, the contracting officer listed in the BAA.
• Due Date: Submit your proposals through the electronic Contract Proposal Submission (eCPS) website by 3 p.m. Eastern Time on May 24, 2021.